Advertisement

Innovative Vaccines in China

  • Qiyou XiaoEmail author
  • Zhijie An
  • Chenyan Yue
  • Yonghong Ge
  • Peicheng Liu
  • Huirong Pan
  • Lingjiu Liu
  • Ruiju Jiang
  • Yan Li
  • Yamin Wang
Chapter
  • 142 Downloads
Part of the Public Health in China book series (PUBHECH, volume 3)

Abstract

Yongxin Yu is an academician at the Chinese Academy of Engineering and a highly respected person when it comes to Japanese encephalitis (JE) live attenuated vaccine (Fig. 5.1). After the JE vaccine he developed was approved and marketed in 1989, hundreds of million doses have been used, demonstrating the safety and effectiveness of this vaccine under large-scale use. The effectiveness of this vaccine is over 95%, as recognized by the WHO and other international organizations. Academician Yu is one of China’s most famous virologists and experts in biological products; he has received an outstanding contribution award by improving China’s medical health. He is also a renowned scientist in China and in the world with his great contributions. His science is rigorous and realistic; pays attention to the accuracy, reliability, and integrity of the experimental data; and is loved by scientific and technological personnel.

References

  1. 1.
    Plotkin S, Walter A. Vaccines. Philadelphia: W.B. Saunders Company; 1999.Google Scholar
  2. 2.
    Igarashi A. Epidemiology and control of Japanese encephalitis. World Health Stat Q. 1992;45(2–3):299–305.PubMedGoogle Scholar
  3. 3.
    Paul WS, Moore PS, Karabatsos N, et al. Outbreak of Japanese encephalitis on the island of Saipan, 1990. J Infect Dis. 1993;167:1053–8.CrossRefGoogle Scholar
  4. 4.
    Hanna JN, Ritchie SA, Phillips DA, et al. An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. Med J Aust. 1996;165:256–60.PubMedGoogle Scholar
  5. 5.
    Zhang Yanlin. Vaccinology. Beijing: China Science Press; 2004. p. 1186–212.Google Scholar
  6. 6.
    Yu Yongxin. Development and production of live attenuated SA 14-14-2 vaccine. Beijing: National Institute for the Control of Pharmaceutical and Biological Products; 2000.Google Scholar
  7. 7.
    Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13–15 October 1998. Vaccine. 2000;18(Suppl 2):1–25.CrossRefGoogle Scholar
  8. 8.
    WHO. Weekly Epidemiological Record on 19 Jan 2007.Google Scholar
  9. 9.
    Sohn YM, et al. Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants. Vaccine. 1999;17:2259.CrossRefGoogle Scholar
  10. 10.
    Wijesinghe PR, et al. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine. Vaccine. 2016;34:5923–8.CrossRefGoogle Scholar
  11. 11.
    Chotpitayasunondh T, Sohn YM, Yoksan S, et al. Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand. J Med Assoc Thail. 2012;94(Suppl. 3):S195–203.Google Scholar
  12. 12.
    Liu ZL, Hennessy S, Strom B, et al. Short- term safety of live, attenuated JE vaccine: results of a randomized trial with 26,239 subjects. J Infect Dis. 1997;176:1366.CrossRefGoogle Scholar
  13. 13.
    Hennesey S, et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet. 1996;347(8):1583.CrossRefGoogle Scholar
  14. 14.
    Gatchalian S, et al. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine. 2008;26(18):2234.CrossRefGoogle Scholar
  15. 15.
    WHO position paper on hepatitis A vaccines – June 2012. Weekly epidemiological record. No. 28–29, 2012, 87, 261–276. http://www.who.int/wer
  16. 16.
    Yao G. Clinical spectrum and natural history of viral hepatitis A in a 1988 Shanghai epidemic. In: Hollinger FB, Lemon SM, Margolis HS, editors. Viral hepatitis and liver disease. Baltimore: Williams and Williams; 1991. p. 76–8.Google Scholar
  17. 17.
    CDC. Estimates of disease burden from viral hepatitis. Atlanta: US Department of Health and Human Services, CDC; 2006. Available at http://www.cdc.gov/ncidod/diseases/hepatitis/resource/PDFs/disease_burden.pdfGoogle Scholar
  18. 18.
    Xu Zhiyi, Wang Xuanyi, Zhao Shoujun. Immune effect and immune strategy of live attenuated hepatitis A vaccine. Chin J Prev Med. 2002;36(3):199–201.Google Scholar
  19. 19.
    Gong Jian, Li Rongcheng, Yang Jinye, et al. Protective efficacy of large-scale immunization with a live attenuated hepatitis A vaccine (LA-1 strain). Guangxi Prev Med. 2000;6(5):257–9.Google Scholar
  20. 20.
    Liu Jingye, Li Guangpu, Xie Baosheng, et al. Preparation of freeze-dried live attenuated hepatitis A vaccine. J Microbiol. 2001;21(4):1–4.Google Scholar
  21. 21.
    Wang Junzhi. Vaccine quality control and evaluation, vol. 95. Beijing: People’s Health Publishing House; 2013.Google Scholar
  22. 22.
    Wang Junzhi. Vaccine quality control and evaluation, vol. 99. Beijing: People’s Health Publishing House; 2013.Google Scholar
  23. 23.
    Zhang Y, Zhu Z, Yang WZ, et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010;7:94.CrossRefGoogle Scholar
  24. 24.
    Ooi MH, Wong SC, Lewthwaite P, et al. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9(11):1097–105.CrossRefGoogle Scholar
  25. 25.
    McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;26:91–107.CrossRefGoogle Scholar
  26. 26.
    Ooi MH, Wong SC, Podin Y, et al. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study. Clin Infect Dis. 2007;44:646–56.CrossRefGoogle Scholar
  27. 27.
    Lu HK, Lin TY, Hsia SH, et al. Prognostic implications of myoclonic jerk in children with enterovirus infection. J Microbiol Immunol Infect. 2004;37:82–7.PubMedGoogle Scholar
  28. 28.
    Chinese Center for Disease Control and Prevention. Technical Guideline of Using Inactivated Enterovirus 71 Vaccine. China CDC National Immunization Program. 2016. Available from: www.chinacdc.cn/zxdt/201606/W020160608725047001222.pdf
  29. 29.
    Yu H, Xing W, et al. Hand, foot and mouth disease in China, 2008–12: an epidemiological study. Lancet Infect Dis. 2014;14(4):308–18.CrossRefGoogle Scholar
  30. 30.
    Chan LG, Parashar UD, Lye MS, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis. 2000;31(3):678–83.CrossRefGoogle Scholar
  31. 31.
    Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. N Engl J Med. 1999;341:929–35.CrossRefGoogle Scholar
  32. 32.
    Infectious Agents Surveillance Report. Hand, foot and mouth disease in Japan, 2002–11. IASR. 2012;33:55–6.Google Scholar
  33. 33.
    Chan KP, Goh KT, Chong CY, et al. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis. 2003;9(1):78–85.CrossRefGoogle Scholar
  34. 34.
    Seiff A. Cambodia unravels cause of mystery illness. Lancet. 2012;380(9838):206.CrossRefGoogle Scholar
  35. 35.
    Zhang Y, Tan X, Cui A, et al. Complete genome analysis of the C4 subgenotype strains of enterovirus 71: predominant recombination C4 viruses persistently circulating in China for 14 years. PLoS One. 2013;8(2):e56341.CrossRefGoogle Scholar
  36. 36.
    Chang SC, Li WC, Chen GW, et al. Genetic characterization of enterovirus 71 isolated from patients with severe disease by comparative analysis of complete genomes. J Med Virol. 2012;84(6):931–9.CrossRefGoogle Scholar
  37. 37.
    Cardosa MJ, Perera D, Brown BA, et al. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg Infect Dis. 2003;9(4):461–8.CrossRefGoogle Scholar
  38. 38.
    Huang Y, Zhou Y, Lu H, et al. Characterization of severe hand, foot, and mouth disease in Shenzhen, China, 2009–2013. J Med Virol. 2015;87(9):1471–9.CrossRefGoogle Scholar
  39. 39.
    Beka EJ, Hussaina KM, et al. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine. 2011;29:4829–38.CrossRefGoogle Scholar
  40. 40.
    Mao Q, Cheng T, Zhu F, Li J, Wang Y, et al. The cross-neutralizing activity of enterovirus 71 subgenotype C4 vaccines in healthy Chinese infants and children. PLoS One. 2013;8(11):e79599.CrossRefGoogle Scholar
  41. 41.
    Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, et al. Safety and immunogenicity of a novel human enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, phase I clinical trial. Vaccine. 2012;30(22):3295–303.CrossRefGoogle Scholar
  42. 42.
    Li YP, Liang ZL, Xia JL, Wu JY, Wang L, Song LF, et al. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, randomized, double-blind, placebo-controlled trial. J Infect Dis. 2014;209(1):46–55.CrossRefGoogle Scholar
  43. 43.
    Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–28.CrossRefGoogle Scholar
  44. 44.
    Hu Y-M, Wang X, Wang J-Z, et al. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months. Clin Vaccine Immunol. 2013;20(12):1805–11.CrossRefGoogle Scholar
  45. 45.
    Liang Z, Mao Q, Gao Q, et al. Establishing China’s national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine. 2011;29(52):9668–74.CrossRefGoogle Scholar
  46. 46.
    McMinn PC. Enterovirus vaccines for an emerging cause of brain-stem encephalitis. N Engl J Med. 2014;370:792–4.CrossRefGoogle Scholar
  47. 47.
    Zhang J, Zhang XF, Huang SJ, et al. Long-term efficacy of a hepatitis E vaccine. N Engl J Med. 2015;372(10):914–22.CrossRefGoogle Scholar
  48. 48.
    Balayan MS, Andjaparidze AG, Savinskaya SS, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology. 1983;20(1):23–31.CrossRefGoogle Scholar
  49. 49.
    Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI. Incidence and severity of viral hepatitis in pregnancy. Am J Med. 1981;70:252–5.CrossRefGoogle Scholar
  50. 50.
    Khuroo MS, Kamili S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J Viral Hepat. 2003;10:61–9.CrossRefGoogle Scholar
  51. 51.
    Kumar Acharya S, Kumar Sharma P, Singh R, et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol. 2007;46:387–94.CrossRefGoogle Scholar
  52. 52.
    Hamid SS, Atiq M, Shehzad F, et al. Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology. 2002;36:474–8.CrossRefGoogle Scholar
  53. 53.
    Pischke S, Wedemeyer H. Hepatitis E virus infection: multiple faces of an underestimated problem. J Hepatol. 2013;58:1045–6.CrossRefGoogle Scholar
  54. 54.
    Teshale EH, Howard CM, Grytdal SP, et al. Hepatitis E epidemic, Uganda. Emerg Infect Dis. 2010;16:126–9.CrossRefGoogle Scholar
  55. 55.
    Zhuang H, Cao XY, Liu CB, et al. Epidemiology of hepatitis E in China. J Gastroenterol. 1991;26(Suppl 3(3)):135–8.Google Scholar
  56. 56.
    Zhou YH, Zhuang H. Recent advances in the epidemiological research on hepatitis E in China. Chin J Epidemiol. 2010;31(12):1414–6.Google Scholar
  57. 57.
    Miao N, Zhang GM, Gong XH, et al. The epidemiological analysis of hepatitis E in 2004–2011 in China. Chin J Vaccine Immun. 2013;19(5):451–4.Google Scholar
  58. 58.
    Wu T, Li SW, Zhang J, et al. Hepatitis E vaccine development. Hum Vaccin Immunother. 2012;8(6):823–7.CrossRefGoogle Scholar
  59. 59.
    Zhang J, Liu CB, Li RC, et al. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine. 2009;27(12):1869–74.CrossRefGoogle Scholar
  60. 60.
    Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010;376(9744):895–902.CrossRefGoogle Scholar
  61. 61.
    Ku FC, Dong DX, Shi OS, et al. Poliomyelitis in China. J Infect Dis. 1982;146(4):552–7.CrossRefGoogle Scholar
  62. 62.
    The history of poliomyelitis [EB/OL]. (2012-03-04) [2012-11-20]. http://group.medlive.cn/forum/topic/29561.

Copyright information

© Springer Nature Singapore Pte Ltd. & People's Medical Publishing House, PR of China 2019

Authors and Affiliations

  • Qiyou Xiao
    • 1
    Email author
  • Zhijie An
    • 1
  • Chenyan Yue
    • 1
  • Yonghong Ge
    • 2
  • Peicheng Liu
    • 3
  • Huirong Pan
    • 4
  • Lingjiu Liu
    • 5
  • Ruiju Jiang
    • 6
  • Yan Li
    • 1
  • Yamin Wang
    • 1
  1. 1.National Immunization Program, Chinese Center for Disease Control and PreventionBeijingChina
  2. 2.General Director Office, Chengdu Institute of Biological Products Co. Ltd.ChengduChina
  3. 3.Department of MarketingBeijing Sinovac Biotech Co. Ltd.BeijingChina
  4. 4.Department of Vaccine Research & DevelopmentXiamen Innovax Biotech Co. Ltd.XiamenChina
  5. 5.Vaccine Division 2Changchun Institute of Biological Products Co. Ltd.JilinChina
  6. 6.Institute of Medical BiologyChinese Academy of Medical SciencesBeijingChina

Personalised recommendations